(Total Views: 492)
Posted On: 12/22/2020 8:24:46 AM
Post# of 72440
OM Competition News: Earlier this year we found out OGEN aka Oragenics’s AG013 was not statistically significant against OM in their trial.
Today Soligenix also announced their P3 OM results:
“We are obviously very disappointed with the unanticipated outcome of the study,” stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. “Despite the fact that SGX942 demonstrated clinically meaningful reductions in oral mucositis consistent with the Phase 2 study, the Phase 3 trial did not achieve the statistically significant benefit we expected.
Today Soligenix also announced their P3 OM results:
“We are obviously very disappointed with the unanticipated outcome of the study,” stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. “Despite the fact that SGX942 demonstrated clinically meaningful reductions in oral mucositis consistent with the Phase 2 study, the Phase 3 trial did not achieve the statistically significant benefit we expected.
(5)
(0)Scroll down for more posts ▼
